947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Lorenza Rimassa, S.L. Chan, Bruno Sangro, George Lau, M. Kudo, В. В. Бредер, M. Varela, Oxana Crysler, M. Bouattour, Tu Van Dao, Adilson Faccio, Junji Furuse, L-B. Jeng, Y-K. Kang, R.K. Kelley, Michael J. Paskow, M. Makowsky, Di Ran, A. Negro, G.K. Abou-Alfa
Topics & Concepts
DurvalumabTremelimumabMedicineHepatocellular carcinomaInternal medicineOncologyPhases of clinical researchCancer researchChemotherapyCancerImmunotherapyNivolumabIpilimumabHepatocellular Carcinoma Treatment and PrognosisCancer, Hypoxia, and MetabolismLiver Disease Diagnosis and Treatment